bremelanotide

There is an astonishing lack of talk on here about a drug which attempts to address something that we talk about all the time and have zero tools to fix - libido. Now that we have multiple phase three studies to review on Pubmed and an FDA approved product perhaps we need to start gathering...

FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women PT-141 AKA Bremelanotide AKA Vyleesi approved. This should open up a whole new focus on the melanocortin system and allow for crowdsourcing the best dosing/timing. It seems something good is happening in...

Rekynda (bremelanotide), an investigational product, is thought to possess a novel mechanism of action, activating endogenous melanocortin pathways involved in sexual desire and response. The two Phase 3 studies for HSDD in pre-menopausal women consisted of double-blind placebo-controlled...